---

Two corrupt companies were in rocky financial territory just a few weeks ago. Now, with concerns over a global monkeypox outbreak being hyped by media and global health organisations alike, the worries – and sins – of these two companies are quickly being forgotten.

By Whitney Webb, 20 May 2022

In recent days, concern over a global outbreak of monkeypox, a mild disease related to smallpox and chickenpox, has been hyped in the media and health ministries around the world, even prompting an emergency meeting at the World Health Organisation (“WHO”). For some, fears have centred around monkeypox being the potential “next pandemic” after Covid. For others, the fear is that monkeypox will be used as the latest excuse to further advance draconian biosecurity policies and global power grabs.

Regardless of how the monkeypox situation plays out, two companies are already cashing in. As concern over monkeypox has risen, so too have the shares of Emergent Biosolutions and SIGA Technologies. Both companies essentially have monopolies in the US market, and other markets as well, on smallpox vaccines and treatments. Their main smallpox-focused products are, conveniently, also used to protect against or treat monkeypox as well. As a result, the shares of Emergent Biosolutions climbed 12% on Thursday, while those of SIGA soared 17.1%.

For these companies, the monkeypox fears are a godsend, specifically for SIGA, which produces a smallpox treatment, known by its brand name TPOXX. It is SIGA’s only product. While some outlets have noted that the rise in the valuation of SIGA Technologies has coincided with recent concerns about monkeypox, essentially no attention has been given to the fact that the company is apparently the only piece of a powerful billionaire’s empire that isn’t currently crumbling.

That billionaire, “corporate raider” Ron Perelman, has deep and controversial ties to the Clinton family and the Democratic party as well as troubling ties to Jeffery Epstein. Aside from his controlling stake in SIGA, Perelman has recently made headlines for rapidly liquidating many of his assets in a desperate bid for cash.

Similarly, Emergent Biosolutions have also been in hot water. The company, which has troubling ties to the 2001 Anthrax attacks, came under fire just under two weeks ago for engaging in a “cover-up” over quality control issues relating to their production of Covid vaccines. A Congressional investigation found that quality control concerns at an Emergent-run facility led to more than 400 million doses of Covid vaccines being discarded. The Emergent factory in question had been shut down by the FDA in April 2021. They were allowed to reopen last August before the government terminated the contract. Given that the majority of the company’s business is tied to US government contracts, the loss of this contract, and the accompanying poor publicity, the news that its smallpox vaccine may soon be of international interest is likely seen as a godsend by the company.

Notably, this is the second time in a year that both companies have benefitted from pandemic or bioterror fears propagated by the media. Last November, speculation rose that a re-emergence of the eradicated virus that causes smallpox would soon take place. This first began with Bill Gates’ comments on the prospects of smallpox bioterrorism during a 4 November 2021 interview and was followed by the 16 November announcement of a CDC/FBI investigation into 15 suspicious vials labelled “smallpox” at a Merck facility in Philadelphia. Now, roughly six months later, the same fears are again paying off for the same two companies.

It seems the fear being generated around monkeypox is not only boosting shares for these two rotten companies, but it’s also helping the public forget their past sins.

The above is the introduction to Whitney Webb’s article ‘Monkeypox Fears May Rescue Endangered Corporations’ published on Unlimited Hangout.  Read the full article HERE.